TW282467B - - Google Patents

Info

Publication number
TW282467B
TW282467B TW081100762A TW81100762A TW282467B TW 282467 B TW282467 B TW 282467B TW 081100762 A TW081100762 A TW 081100762A TW 81100762 A TW81100762 A TW 81100762A TW 282467 B TW282467 B TW 282467B
Authority
TW
Taiwan
Prior art keywords
compounds
angiotensin
aii
mammals
alleviate
Prior art date
Application number
TW081100762A
Other languages
English (en)
Chinese (zh)
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of TW282467B publication Critical patent/TW282467B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/91Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Fats And Perfumes (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW081100762A 1991-01-30 1992-01-31 TW282467B (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64849291A 1991-01-30 1991-01-30

Publications (1)

Publication Number Publication Date
TW282467B true TW282467B (en:Method) 1996-08-01

Family

ID=24601009

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081100762A TW282467B (en:Method) 1991-01-30 1992-01-31

Country Status (23)

Country Link
US (2) US5290780A (en:Method)
EP (1) EP0497150B1 (en:Method)
JP (1) JP2758766B2 (en:Method)
KR (1) KR920014805A (en:Method)
CN (1) CN1037440C (en:Method)
AT (1) ATE164158T1 (en:Method)
AU (2) AU642573B2 (en:Method)
CA (1) CA2060154A1 (en:Method)
CZ (1) CZ281429B6 (en:Method)
DE (1) DE69224763T2 (en:Method)
DK (1) DK0497150T3 (en:Method)
ES (1) ES2117014T3 (en:Method)
FI (1) FI920217A7 (en:Method)
GR (1) GR3026592T3 (en:Method)
HU (1) HUT61748A (en:Method)
IE (1) IE920142A1 (en:Method)
IL (1) IL100711A0 (en:Method)
NO (1) NO920298L (en:Method)
NZ (1) NZ241343A (en:Method)
PL (1) PL293316A1 (en:Method)
SK (1) SK279004B6 (en:Method)
TW (1) TW282467B (en:Method)
ZA (1) ZA92392B (en:Method)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290780A (en) * 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5385894A (en) * 1991-03-06 1995-01-31 Merck & Co., Inc. Disubstituted 6-aminoquinazolinones
EP0618207B1 (en) * 1993-03-24 1999-01-07 American Home Products Corporation Substituted pyridopyrimidines as antihypertensives
US5358951A (en) * 1993-04-23 1994-10-25 American Cyanamid Company Angiotensin II receptor blocking 2, 3, 6 substituted quinazolinones
US5610301A (en) * 1993-07-01 1997-03-11 American Cyanamid Company Process for the regioselective n-alkylation of quinazolinones
US5342944A (en) * 1993-07-19 1994-08-30 American Cyanamid Company Process for the preparation of 2-alkyl-3,5,6,7- or 8-substituted-4(3H)-quinazolinones
US5338736A (en) * 1993-10-07 1994-08-16 American Cyanamid Company Angiotensin II receptor blocking 2,3,6-substituted quinazolinones
WO1996009301A1 (en) * 1994-09-20 1996-03-28 Wakunaga Seiyaku Kabushiki Kaisha Process for producing n-biphenylmethylthiadiazoline derivative or salt thereof and intermediate for producing the same
CZ390097A3 (cs) * 1995-06-07 1998-06-17 American Home Products Corporation Způsob přípravy derivátů bifenylu
US5760220A (en) * 1995-06-07 1998-06-02 American Home Products Corporation Process for preparation of biphenyl derivatives
US5739330A (en) * 1996-02-05 1998-04-14 Hoechst Celanese Corporation Process for preparing quinazolones
US5763608A (en) * 1996-02-05 1998-06-09 Hoechst Celanese Corporation Process for preparing pyrimidine derivatives
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
GB0223730D0 (en) * 2002-10-11 2002-11-20 Novartis Ag Organic compounds
CN1706169A (zh) * 2002-10-18 2005-12-07 皇家飞利浦电子股份有限公司 用于即时电视中的元数据保护的方法、系统、装置、信号和计算机程序产品
EP1558260A4 (en) * 2002-11-04 2006-10-25 Nps Pharma Inc CHINAZOLINONE COMPOUNDS AS CALCILYTIC
GB0412769D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
EP2079739A2 (en) * 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
BR112014030473A2 (pt) 2012-06-13 2017-06-27 Hoffmann La Roche novo diazaespirocicloalcano e azaespirocicloalcano
SI2900669T1 (sl) 2012-09-25 2019-12-31 F. Hoffmann-La Roche Ag Derivati heksahidropirolo(3,4-C)pirola in sorodne spojine kot zaviralci avtotaksina (ATX) in kot zaviralci tvorbe lizofosfatidne kisline (LPA) za zdravljenje npr. bolezni ledvic
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
JP6496730B2 (ja) 2013-11-26 2019-04-03 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規なオクタヒドロ−シクロブタ[1,2−c;3,4−c’]ジピロール−2−イル
MX370659B (es) 2014-03-26 2019-12-19 Hoffmann La Roche Compuestos bicíclicos como inhibidores de producción de autotaxina (atx) y ácido lisofosfatídico (lpa).
MX373236B (es) 2014-03-26 2020-05-08 Hoffmann La Roche Compuestos condensados de [1,4]diazepina como inhibidores de producción de la autotaxina (atx) y ácido lisofosfatidico (lpa).
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MX387736B (es) 2015-09-04 2025-03-18 Hoffmann La Roche Derivados de fenoximetilo.
CA2984585A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
PE20180461A1 (es) 2015-09-24 2018-03-06 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de la atx
KR20180054634A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 신규한 이환형 화합물
KR20180054635A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서 이환형 화합물
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
CN110392679B (zh) 2017-03-16 2023-04-07 豪夫迈·罗氏有限公司 可用作双重atx/ca抑制剂的杂环化合物
CN107056715B (zh) * 2017-04-07 2019-07-30 江南大学 一种增强TRPV4-KCa2.3复合体耦联度的化合物及其在抗高血压中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) * 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
MX7829A (es) * 1986-08-21 1993-08-01 Pfizer Quinazolindionas y piridopirimindionas y procedimiento para su preparacion
CS272018B1 (en) * 1988-11-01 1990-12-13 Fisnerova Ludmila Ethereal derivatives of 4/3h/-quinazolinone
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
US5240928A (en) * 1989-07-03 1993-08-31 Merck & Co., Inc. Substituted quinazolinones as angiotensin II antagonists
EP0407342A3 (en) * 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
CA2037630C (en) * 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
CA2053148A1 (en) * 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
US5290780A (en) * 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones

Also Published As

Publication number Publication date
EP0497150A1 (en) 1992-08-05
SK279004B6 (sk) 1998-05-06
JPH0578332A (ja) 1993-03-30
AU4490693A (en) 1993-11-18
ZA92392B (en) 1992-10-28
AU642573B2 (en) 1993-10-21
KR920014805A (ko) 1992-08-25
JP2758766B2 (ja) 1998-05-28
NZ241343A (en) 1994-06-27
HU9200278D0 (en) 1992-04-28
NO920298D0 (no) 1992-01-22
ATE164158T1 (de) 1998-04-15
AU1039792A (en) 1992-08-06
EP0497150B1 (en) 1998-03-18
HUT61748A (en) 1993-03-01
DK0497150T3 (da) 1998-06-02
ES2117014T3 (es) 1998-08-01
CZ281429B6 (cs) 1996-09-11
FI920217L (fi) 1992-07-31
NO920298L (no) 1992-07-31
FI920217A0 (fi) 1992-01-17
DE69224763D1 (de) 1998-04-23
GR3026592T3 (en) 1998-07-31
FI920217A7 (fi) 1992-07-31
CS25592A3 (en) 1992-08-12
US5290780A (en) 1994-03-01
IL100711A0 (en) 1992-09-06
CN1037440C (zh) 1998-02-18
DE69224763T2 (de) 1998-07-09
CN1066847A (zh) 1992-12-09
AU647992B2 (en) 1994-03-31
CA2060154A1 (en) 1992-07-31
PL293316A1 (en) 1993-08-23
US5405849A (en) 1995-04-11
IE920142A1 (en) 1992-07-29

Similar Documents

Publication Publication Date Title
TW282467B (en:Method)
EP0403159A3 (en) Imidazolyl-alkenoic acids
SG47626A1 (en) Substituted pyrimidines
PL287631A1 (en) Method of obtaining novel substituted derivatives of n-/imidazolil/-alkyl-alamine
AU3635893A (en) Triazolopyrimidin derivatives as antiotensin II receptor antagonists
AU585379B2 (en) Process for preparing 2-acyl-3,4-dialkoxyanilines